
The World Market for Molecular Diagnostics Tests, 11th Edition
Description
The World Market for Molecular Diagnostics Tests, 11th Edition
Overall Market
This market is heavily competitive. Companies considered include:
This has powered this segment for high market growth over other major diagnostic platforms commonly used for infectious disease testing such as immunoassay and ID/AST. Molecular detection platforms are increasingly being recognized for the improved sensitivity and specificity they can offer, even though they are more expensive. The report offers global analysis of the molecular infectious disease diagnostics segment, as well as analysis of subsegments that include CT/NG, HPV, hepatitis, HIV, HAIs, respiratory diseases, and tuberculosis:
It is notable that the first category where molecular diagnostics earned their place was infectious disease. In this category, specific results were needed for treatment decisions. The pioneers in the molecular diagnostics field include Roche Diagnostics, Gen-Probe, and Becton Dickinson. The main focus of the initial molecular diagnostics products was infectious disease including HIV, Chlamydia Trachomatis/Neisseria Gonorrhoea (CT/NG), and TB. These diseases are still critical components of the market. Recently growth in molecular diagnostics methods has also been coming from inherited diseases, cancer, coagulation, and other areas.
Overall Market
- Infectious Disease Molecular Diagnostics (COVID-19, Hepatitis, HIV, Respiratory, STI, HAIs, Others)
- Cancer Molecular Diagnostic Markets (Blood-based and Tissue-based)
- Genetic Molecular Diagnostic Markets (SNPs, Inherited, NIPT, Other)
- Blood Banking Molecular Diagnostics Markets
- Transplantation Molecular Diagnostic Markets
- Regional Molecular Diagnostics Markets (North America, Europe, Asia, Global)
This market is heavily competitive. Companies considered include:
- Roche
- Abbott
- Thermo Fisher
- Meridian Bioscience
- Myriad
- Perkin Elmer
- Cepheid
- BioMérieux
- Promega
- QuantuMDX
- QuidelOrtho
- Hologic
- Qiagen
- ARUP
- Asuragen
- CareDX
- Vela Diagnostics
- Becton, Dickinson &Co.
- BGI
- Bio-Rad
- Leica Biosystems
- Greiner Bio-One
- Biocartis
- Credo
- Eiken
- CTK
- Leica Biosystems
- Grifols
- Illumina
- T2
This has powered this segment for high market growth over other major diagnostic platforms commonly used for infectious disease testing such as immunoassay and ID/AST. Molecular detection platforms are increasingly being recognized for the improved sensitivity and specificity they can offer, even though they are more expensive. The report offers global analysis of the molecular infectious disease diagnostics segment, as well as analysis of subsegments that include CT/NG, HPV, hepatitis, HIV, HAIs, respiratory diseases, and tuberculosis:
It is notable that the first category where molecular diagnostics earned their place was infectious disease. In this category, specific results were needed for treatment decisions. The pioneers in the molecular diagnostics field include Roche Diagnostics, Gen-Probe, and Becton Dickinson. The main focus of the initial molecular diagnostics products was infectious disease including HIV, Chlamydia Trachomatis/Neisseria Gonorrhoea (CT/NG), and TB. These diseases are still critical components of the market. Recently growth in molecular diagnostics methods has also been coming from inherited diseases, cancer, coagulation, and other areas.
- Global Molecular Infectious Disease Diagnostics Markets (2022-2027), By Infection (Hepatitis, HIV, HAIs/Sepsis, HPV, CT/NG, Respiratory diseases, Mycobacteria/TB, Other, Total) ($, Million)
- Global Molecular Infectious Disease Diagnostics Markets, by Region (2022-2027)
- Global Molecular HPV Testing Markets, By Region (2022-2027)
- Global Molecular CT/NG Testing Markets, By Region (2022-2027)
- Global Molecular Hepatitis Testing Markets, By Region (2022-2027)
- Global Molecular HIV Testing Markets,
- Global Molecular HAIs/Sepsis Testing Markets,
- Global Molecular Respiratory Diseases Testing Markets
- Global Molecular Mycobacteria/TB Testing Markets
- Global Molecular Blood Screening Diagnostics Markets, By Region (2022-2027) ($, Million)
- Global Molecular Histology and Cytology Diagnostics Markets by Application (2022-2027) (Cancer, Inherited diseases, Infectious/Other, Total) ($, Million)
- Global Molecular Histology and Cytology Diagnostics Markets, by Region (2022-2027) ($, Million)
- Global Molecular Histology Diagnostics Markets, by Region (2022-2027) l) ($, Million)
- Global Molecular Cancer Diagnostics Markets, By Region (2022-2027) (North America, Europe, APAC, RoW, Total) ($, Million) The molecular transplant diagnostics space is a competitive market with many companies offering PCR-based and bead-array-based test kits based on the HLA genes that have been characterized. The demand for NGS has been growing in the segment. An HLA test requires that some six genes are screened in parallel, with each displaying about 100 important (known) local variants. This requirement lends itself to technologies such as microarrays and sequencing that can screen for many targets. The report outlines the markets for molecular transplant diagnostics by geography:
- Global Molecular Transplant Diagnostics Markets, By Region (2022-2027) ($, Million)
- Global Molecular Genetic Diagnostics Markets, By Disease Segments (2022-2027) (Inherited, Thrombophilia [SNP tests] & Coagulation Markers, NIPT, Others, Total) ($, Million)
Table of Contents
297 Pages
- Size of Molecular Diagnostics Market
- Growth Areas in Molecular Diagnostics
- Recent Developments
- Other 2022 Developments in Molecular Diagnostics
- Major IVD Players See Decline in COVID-19 Sales
- North America
- Europe
- APAC
- Latin America
- Rest-of-World
- COVID Testing Market Computation Methodology
- Test Vendors
- Brisk Recent Activity
- Market Size and Forecast by Segments
- Infectious Diseases
- NAT Blood Screening
- Molecular Histology and Cytology Diagnostics
- HPV
- Markets for Molecular Cancer Diagnostics
- Molecular Transplant Diagnostics
- Molecular Inherited Diseases Diagnostics
- Molecular Diagnostics Market Deals, Collaborations, Acquisitions
- Sequencing
- Lab Automation and Molecular Diagnostics
- CRISPR and Molecular Diagnostics
- Abbott Diagnostics
- Advanced Cell Diagnostics (Bio-Techne)
- Agena Bioscience
- Agendia BV
- Agilent Technologies (incl. Dako)
- Aidian Oy
- Altona Diagnostics
- Amoy Diagnostics
- Applied Spectral Imaging
- ARUP Laboratories
- Asuragen Inc. (Bio-Techne)
- Becton, Dickinson & Co. (BD)
- Beijing Genomics Institute (BGI)
- Berry Genomics
- binx health
- Bio-Rad Laboratories, Inc.
- Biocartis
- Biodesix
- Biomeme, Inc
- bioMérieux
- Bioneer
- CareDx, Inc.
- Credo Bioscience
- CTK Biotech
- Danaher (Cepheid and Leica Biosystems)
- DiaSorin
- Eiken Chemical
- Exact Sciences Corp.
- GenMark Diagnostics (Roche)
- Genotypic Technology Pvt. Ltd.
- Greiner Bio-One GmbH
- Grifols, S. A
- Hologic, Inc.
- Illumina, Inc.
- Immucor, Inc.
- Meridian Bioscience Inc
- Molbio Diagnostics Pvt. Ltd.
- Myriad Genetics, Inc.
- NanoString Technologies, Inc.
- NeuroMoDX
- Oxford Nanopore Technologies Ltd
- PerkinElmer Inc.
- Promega Corporation
- Qiagen
- QuantuMDx Group
- QuidelOrtho
- Rheonix, Inc.
- Roche Diagnostics
- Seegene
- Sekisui Diagnostics LLC
- Sherlock Biosciences
- SOLVD Health (AutoGenomics)
- Standard BioTools
- T2 Biosystems
- Thermo Fisher Scientific Inc.
- Vela Diagnostics
- Veracyte, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.